TrialPloS one2018

Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial.

Edgar Turner Overton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.